Showing Latest Articles
Acura Pharmaceuticals and King Pharmaceuticals Announce Positive Top Line Results of a Clinical Study Assessing Relative Abuse Potential
King Pharmaceuticals, 03/09/2010
Free full text
Study 114 top–line results demonstrate that two different potentially abused excess oral doses of Acurox Tablets are significantly disliked compared to equivalent excess oral doses of oxycodone HCl tablets alone. All five co–primary endpoints comparing the like/dislike of excess doses of Acurox Tablets with the like/dislike of excess doses of oxycodone HCl tablets alone each achieved statistical significance.
